Jane Wasman
CIK 1352455 · President, Intl and GC · last filed 2026-05-19
Jane Wasman is a President, Intl and GC who has filed 87 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for RIGL, was dated May 19, 2026. Across all open-market trades the lifetime net is −$7.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.0M across reported positions. 12 SEC filings were submitted jointly with Galena Biopharma, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ACOR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
420 SAW MILL RIVER ROAD
ARDSLEY, NY 10502
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RIGL | Director | 18,250 | $49.91 | $910.9K | $0 | 9 | 2026-05-19 |
| SLS | Director | 92,900 | $11.34 | $1.05M | $33.8K | 11 | 2026-01-09 |
| ATHERSYS, INC / NEW (ATHX) Delisted | Director | 35,141 | $0.01 | $474 | $0 | 4 | 2023-01-11 |
| Acorda Therapeutics, Inc. (ACOR) Delisted | President, Intl and GC | 978 | $0.66 | $646 | -$7.69M | 63 | 2019-12-04 |
Recent Filings
87 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-19 | RIGL | Grant (A) | +5,750 | $0 | EDGAR |
| 2026-01-09 | SLS | Grant (A) | +50,000 | $0 | EDGAR |
| 2025-06-02 | SLS | Buy (P) | +20,000 | $33.8K | EDGAR |
| 2025-05-28 | RIGL | Grant (A) | +2,500 | $0 | EDGAR |
| 2025-01-14 | SLS | Grant (A) | +12,500 | $0 | EDGAR |
| 2024-05-29 | RIGL | Grant (A) | +25,000 | $0 | EDGAR |
| 2024-01-25 | SLS | Grant (A) | +6,000 | $0 | EDGAR |
| 2023-07-12 | RIGL | Grant (A) | +25,000 | $0 | EDGAR |
| 2023-02-03 | SLS | Grant (A) | +2,500 | $0 | EDGAR |
| 2023-01-11 | ATHERSYS, INC / NEW (ATHX) Delisted | Grant (A) | +22,321 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.